By Jeff Stewart, Linda Morini and Mike Occhipinti
The top ten pharmaceutical companies spend more on marketing and sales than on research & development. A similar amount is spent on line items such as insurance company rebates to ensure patients can access the drugs their doctors prescribe. A pharmaceutical company may spend twice as much getting the patient to the retail pharmacy counter as it spends on inventing and testing drugs in the first place. What happens next? What does the patient do when making the final decision to which all this investment has led?
Medicines are worthless if people don’t take them and the consequences for patients and the healthcare system as a whole are significant. Nearly $300 billion is lost in additional avoidable medical spending each year when patients don’t take their medicines as prescribed.
In our first annual Patient Adherence Influence Report, two INC Research/inVentiv Health companies – Adheris Health and inVentiv Health Consulting – set out to understand the most influential factors driving patient adherence or non-adherence and to answer the question: Will the patient cross the finish line at the retail pharmacy, or will he or she walk away?